Publications

BibTex format

@article{Crawford:2018:10.3310/hta22170,
author = {Crawford, MJ and Sanatinia, R and Barrett, B and Cunningham, G and Dale, O and Ganguli, P and Lawrence-Smith, G and Leeson, VC and Lemonsky, F and Lykomitrou-Matthews, G and Montgomery, A and Morriss, R and Munjiza, J and Paton, C and Skorodzien, I and Singh, V and Tan, W and Tyrer, P and Reilly, JG},
doi = {10.3310/hta22170},
journal = {HEALTH TECHNOLOGY ASSESSMENT},
pages = {1--+},
title = {Lamotrigine for people with borderline personality disorder: a RCT},
url = {http://dx.doi.org/10.3310/hta22170},
volume = {22},
year = {2018}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background:No drug treatments are currently licensed for the treatment of borderline personality disorder (BPD). Despite this, people with this condition are frequently prescribed psychotropic medications and often with considerable polypharmacy. Preliminary studies have indicated that mood stabilisers may be of benefit to people with BPD.Objective:To examine the clinical effectiveness and cost-effectiveness of lamotrigine for people with BPD.Design:A two-arm, double-blind, placebo-controlled individually randomised trial of lamotrigine versus placebo. Participants were randomised via an independent and remote web-based service using permuted blocks and stratified by study centre, the severity of personality disorder and the extent of hypomanic symptoms.Setting:Secondary care NHS mental health services in six centres in England.Participants:Potential participants had to be aged ≥ 18 years, meet diagnostic criteria for BPD and provide written informed consent. We excluded people with coexisting psychosis or bipolar affective disorder, those already taking a mood stabiliser, those who spoke insufficient English to complete the baseline assessment and women who were pregnant or contemplating becoming pregnant.Interventions:Up to 200 mg of lamotrigine per day or an inert placebo. Women taking combined oral contraceptives were prescribed up to 400 mg of trial medication per day.Main outcome measures:Outcomes were assessed at 12, 24 and 52 weeks after randomisation. The primary outcome was the total score on the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) at 52 weeks. The secondary outcomes were depressive symptoms, deliberate self-harm, social functioning, health-related quality of life, resource use and costs, side effects of treatment and adverse events. Higher scores on all measures indicate poorer outcomes.Results:Between July 2013 and October 2015 we randomised 276 participants, of whom 195 (70.6%) were followed up 52
AU  - Crawford,MJ
AU  - Sanatinia,R
AU  - Barrett,B
AU  - Cunningham,G
AU  - Dale,O
AU  - Ganguli,P
AU  - Lawrence-Smith,G
AU  - Leeson,VC
AU  - Lemonsky,F
AU  - Lykomitrou-Matthews,G
AU  - Montgomery,A
AU  - Morriss,R
AU  - Munjiza,J
AU  - Paton,C
AU  - Skorodzien,I
AU  - Singh,V
AU  - Tan,W
AU  - Tyrer,P
AU  - Reilly,JG
DO  - 10.3310/hta22170
EP  - 1
PY  - 2018///
SN  - 1366-5278
SP  - 1
TI  - Lamotrigine for people with borderline personality disorder: a RCT
T2  - HEALTH TECHNOLOGY ASSESSMENT
UR  - http://dx.doi.org/10.3310/hta22170
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000429865200001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/58818
VL  - 22
ER  -

Download

ProfessorMikeCrawford

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)